« Back Research in Social and Administrative Pharmacy

Article in Press

Prescribing trends for management of congestive heart failure from 2002 to 2004

  • Tonya Crawford, Pharm.D.

      Affiliations

    • Department of Pharmacy, University of Illinois at Chicago Medical Center, Chicago, IL 60612, USA
    • ,
  • Larry W. Segars, Pharm.D., Dr. P.H., F.C.C.P., B.C.P.S.

      Affiliations

    • Departments of Pharmacology/Microbiology & Preventive Medicine, Kansas City University of Medicine & Biosciences, Kansas City, MO 64106, USA
    • ,
  • Rafia S. Rasu, M.Pharm., M.B.A., Ph.D.

      Affiliations

    • School of Pharmacy, University of Missouri-Kansas City, 4247 New Health Sciences Building, 2464 Charlotte Street, Kansas City, MO 64108, USA
    • Corresponding Author InformationCorresponding author. Department of Pharmacy Practice and Administration, Schools of Pharmacy and Nursing, University of Missouri-Kansas City, 4247 New Health Sciences Building, 2464 Charlotte Street, Kansas City, MO 64108, USA. Tel.: +1 816 235 5498; fax: +1 816 235 6008.

Published online 22 September 2009 Corrected Proof

References 

  1. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics—2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119(3):e21–181
  2. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics—2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117:e25–146
  3. Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009;53(15):e1–e90
  4. Xuan J, Duong PT, Russo PA, Lacey MJ, Wong B. The economic burden of congestive heart failure in a managed care population. Am J Manag Care. 2000;6:693–700
  5. Konstam MA, Dracup K, Baker DW, et al. Heart failure: evaluation and care of patients with left ventricular systolic dysfunction. J Card Fail. 1995;1:183–187
  6. Bungard TJ, McAlister FA, Johnson JA, et al. Underutilisation of ACE inhibitors in patients with congestive heart failure. Drugs. 2001;61(14):2021–2033
  7. Philbin EF, Andreaou C, Rocco TA, Lynch LJ, Baker SL. Patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure in two community hospitals. Am J Cardiol. 1996;77:832–838
  8. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med. 1987;316:1429–1435
  9. Cherry DK, Hing E, Woodwell DA, Rechtsteiner EA. National Ambulatory Medical Care Survey: 2006 summary. Natl Health Stat Rep. 2008;1–39
  10. Ambulatory Health Care Data . Available at: http://www.cdc.gov/nchs/about/major/ahcd/ahcd1.htm2008;Accessed 06.04.08
  11. Philbin EF. Factors determining angiotensin-converting enzyme inhibitor underutilization in heart failure in a community setting. Clin Cardiol. 1998;21:103–108
  12. Stafford R, Saglam D, Blumenthal D. National patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure. Arch Intern Med. 1997;157:2460–2464
  13. Smith N, Psaty B, Pitt B, Garg R, Gottdiener J, Heckbert S. Temporal patterns in the medical treatment of congestive heart failure with angiotensin-converting enzyme inhibitors in older adults, 1989 through 1995. Arch Intern Med. 1998;158:1074–1080
  14. Allen LaPointe NM, Zhou Y, Stafford JA, et al. Association between mortality and persistent use of beta blockers and angiotensin-converting enzyme inhibitors in patients with left ventricular systolic dysfunction and coronary artery disease. Am J Cardiol. 2009;103:1518–1524
  15. Shah R, Wang Y, Foody JM. Effect of statins, angiotensin-converting enzyme inhibitors, and beta blockers on survival in patients ≥65 years of age with heart failure and preserved left ventricular systolic function. Am J Cardiol. 2008;101:217–222
  16. Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol. 2003;41:1529–1538
  17. Adams KF, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149:209–216
  18. Peacock Wf IV, Fonarow GC, Emerman CL, et al. Impact of early initiation of intravenous therapy for acute decompensated heart failure on outcomes in ADHERE. Cardiology. 2007;107:44–51
  19. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF) . Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287:1531–1540

PII: S1551-7411(09)00075-8

doi: 10.1016/j.sapharm.2009.06.004

« Back Research in Social and Administrative Pharmacy

Article in Press

Article Tools

* Image Usage & Resolution